Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets - Trial NCT04868981
Access comprehensive clinical trial information for NCT04868981 through Pure Global AI's free database. This Phase 1 trial is sponsored by Fujian Cosunter Pharmaceutical Co. Ltd and is currently Completed. The study focuses on Hepatitis B. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fujian Cosunter Pharmaceutical Co. Ltd
Timeline & Enrollment
Phase 1
May 31, 2021
Mar 14, 2022
Primary Outcome
Number of patients with chronic HBV infection with treatment-related adverse events and laboratory abnormalities.,Cmax of GST-HG141,AUC of GST-HG141,t1/2 of GST-HG141,Cl/F of GST-HG141
Summary
To Evaluate the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets in
 Multiple-center, Randomized, Double-blind, Placebo-controlled Multiple-dose,
 Multiple-administration Study in Patients With Chronic Hepatitis B (CHB)
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04868981
Non-Device Trial